2 Result: Arcellx
Arcellx's IND Clinical Hold and Rhythm Pharma's Breakthrough: Weight Loss in HyOb Patients
June 20th, 2023
Arcellx, Inc. (Nasdaq: ACLX) said that its CART-ddBCMA investigational new drug (IND) for the treatment of relapsed or refractory multiple myeloma (rrMM) has been placed on clinical hold by the U.S. Food and Drug Administration (FDA). The cl. Read more
Initiated with a Buy: Arcellx, Pliant Therapeutics, Tarsus Pharmaceuticals, Varonis Systems
May 18th, 2023
Several companies have recently received initiations with Buy ratings from prominent financial institutions, indicating positive outlooks for their future performance. Arcellx, Inc. (Nasdaq: ACLX) has been initiated with a Buy rating and a price t. Read more
Want To Find Some News?
News By Industries
Recent Post
-
FTC Takes Action to Prevent Anticompetitive Arrangement in Beretta, Ruger Deal
September 16th, 2026Why Opponent Preparation Matters for Post-Graduate Athletes
September 16th, 2026The Work Behind the Game: How Football Teams Prepare to Compete
September 15th, 2026NJCP Operates on a Prep Model Built Around a Full Season
September 14th, 2026Earnings Preview: High Tide, Kestra Medical, and RF Industries in Focus
September 12th, 2026
Member Login